Solaris Endovascular has filed a notice of an exempt offering of securities to raise $10 Million in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Solaris Endovascular is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Solaris Endovascular
Solaris Endovascular develops innovative vascular solutions for dialysis access and peripheral artery disease (PAD). The company uses a proven stent platform and drug-eluting technology to create next-generation electrospinning PTFE-covered stent grafts. Its vision is to extend the patency of dialysis access grafts, fistulas, and peripheral arteries, helping patients live healthier lives with fewer medical interventions. Solaris Endovasculars products are already proven in global markets, with more than 13,000 units sold to date. The company focuses on addressing critical needs among people with end-stage kidney disease and PAD while improving patient outcomes and quality of life.

To learn more, visit https://www.solarisendovascular.com/
LinkedIn: https://www.linkedin.com/company/solaris-endovascular/

Contact:
Randolph Hubbell, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.